Similar articles

Abstract: Objective: To evaluate the effect of topical corticosteroid for treatment of moderate or severe dry eye. Methods: Sixty eyes of 30 patients with moderate or severe dry eye, who were not sensitive to artificial tears, were treated with 0.1% fluorometholone eye drops. Subjective symptom and objective tests were used to evaluate the efficacy of treatment before and after application of 0.1% fluorometholone eye drops for 1 week and 1 month. Side effects were also evaluated. Results: After 1 week of treatment, subjective symptoms were improved in all dry eye patients; objective tests were improved in all dry eye patients 1 month after treatment, and the difference was significant. Conclusion: Topical corticosteroid drops can rapidly and effectively relieve the symptoms and signs of moderate or severe dry eye.

[1] Avunduk, A.M., Avunduk, M.C., Varnell, E.D., Kaufman, H.E., 2003. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am. J. Ophthalmol., 136(4):593-602.

[2] Baudouin, C., 2001. The pathology of dry eye. Surv. Ophthalmol., 45(Suppl. 2):S211-S220.

[3] Brignole, F., Pisella, P.J., Goldschild, M., de Saint Jean, M., Goguel, A., Baudouin, C., 2000. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest. Ophthalmol. Vis. Sci., 41(6):1356-1363.

[4] Caccavo, D., Pellegrino, N.M., Altamura, M., Rigon, A., Amati, L., Amoroso, A., Jirillo, A., 2002. Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application. J. Endotoxin. Res., 8(6):403-417.

[5] Gao, J., Morgan, G., Tieu, D., Schwalb, T.A., Luo, J.Y., Wheeler, L.A., Stern, M.E., 2004. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjogrens syndrome-like MRL/lpr mice. Exp. Eye Res., 78(4):823-835.

[6] Johnson, M.E., Murphy, P.J., 2004. Changes in the tear film and ocular surface from dry eye syndrome. Prog. Retin. Eye Res., 23(4):449-474.

[7] Lee, H.K., Ryu, I.H., Seo, K.Y., Hong, S., Kim, H.C., Kim, E.K., 2006. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology, 113(2):198-205.

[8] Mathers, W.D., 2000. Why the eye becomes dry: a cornea and lacrimal gland feedback model. CLAO J., 26(3):159-165.

[9] Nagelhout, T.J., Gamache, D.A., Roberts, L., Brady, M.T., Yanni, J.M., 2005. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye. J. Ocul. Pharmacol. Ther., 21(2):139-148.

[10] Pflugfelder, S.C., 2004. Antiinflammatory therapy for dry eye. Am. J. Ophthalmol., 137(2):337-342.

[11] Pflugfelder, S.C., Maskin, S.L., Anderson, B., Chodosh, J., Holland, E.J., de Palva, C.S., Bartels, S.P., Micuda, T., Proskin, H.E., Vogel, R., 2004. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am. J. Ophthalmol., 138(3):444-457.

[12] Stern, M.E., Beuerman, R.W., Fox, R.I., Gao, J., Mircheff, A.K., Pflugfelder, S.C., 1998. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea, 17(6):584-589.

[13] Stern, M.E., Gao, J., Siemasko, K.F., Beuerman, R.W., Pflugfelder, S.C., 2004. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp. Eye Res., 78(3):409-416.

[14] Yen, M.T., Pflugfelder, S.C., Feuer, W.J., 2001. The effect of punctal occlusion on tear production, tear clearance, and ocular surface sensation in normal subjects. Am. J. Ophthalmol., 131(3):314-323.

[15] Zoukhri, D., 2006. Effect of inflammation on lacrimal gland function. Exp. Eye Res., 82(5):885-898.